Proportion with no hospitalization
FIGURE 3 · Panel _A_
Panel _A_ 是同一 FIGURE 3 中的独立 KM 子图;人群、终点或分析条件以本 Panel 图注语义为准。
Jing Wu, Ann Eriksson-Dufva, Anna Budzianowska, Amalia Feresiadou, William Hansson, Max Albert Hietala, Irene Håkansson, Rune Johansson, Daniel Jons, Ivan Kmezic, Christopher Lindberg, Jonas Lindh, Fredrik Lundin, Ingela Nygren, Anna Rostedt Punga, Rayomand Press, Kristin Samuelsson, Peter Sundström, Oskar Wickberg, Thomas Frisell, Susanna Brauner, Fredrik Piehl
Eur J Neurol 32(11) e70418
BACKGROUND: The placebo-controlled RINOMAX trial (NCT02950155) demonstrated superiority up to 12 months of rituximab over standard-of-care in new-onset generalized myasthenia gravis (MG), but benefit-risk over longer time frames remains unknown. METHODS: RINOMAX included 47 participants with a Quantitative Myasthenia Gravis (QMG) score ≥ 6. Twenty-five patients were randomized to a single intravenous infusion of 500 mg rituximab, and 22 to placebo of which 16 received rituximab after the double-blinded phase (7 ± 2.9 months). Data were extracted from the Swedish MG registry to track hospitalizations, treatments including rescue, and disease activity scores. RESULTS: Compared to the placebo arm, lower mean time-weighted QMG scores at 12 months (mean difference [MD]: 2.9, 95% CI: 0.9, 4.9; p = 0.005) and 24 months (MD: 2.6, 95% CI: 0.3, 4.9; p = 0.027) were observed in the RTX arm. The incidence rate of rescue from 48 weeks up to 5 years was numerically higher in the placebo arm than RTX (0.16 vs. 0.09/person-year; p = 0.121). Compared to delayed RTX, early exposure displayed lower QMG, risk of hospitalization (HR 0.24, 95% CI 0.07, 0.83), and rescue (HR 0.46, 95% CI 0.14, 1.57), but also the six patients never receiving RTX showed lower hospitalization risk (HR 0.08, 95% CI 0.01, 0.96). Corticosteroid doses were low globally throughout. Overall, 12.5% and 18.8% and of patients with early and delayed RTX, respectively, suffered a severe infection. CONCLUSION: Disease activity and treatment burden, including hospitalization and rescue treatments, remained low, indicating a potential benefit of rituximab on the long-term disease trajectory. Infection risk with B cell depletion, however, remains a concern.
1 个 Figure · 4 个 KM 面板
FIGURE 3 Kaplan–Meier estimates of the proportion of no hospitalization and no rescue therapy by initial treatment allocation and treatment timing and the number of patients remaining at risk by months. Hazard ratio and 95% confidence interval were estimated using the proportional hazard model adjusted for age at onset, sex, and previous rescue treatment before 12 months. CI, confidence interval; HR, hazard ratio; RTX, rituximab. The blue and pink lines in the left panel represent the placebo and RTX original allocation, respectively. The blue, pink, and green lines in the right panel represent the late, early, and RTX allocation, respectively.
FIGURE 3 · Panel _A_
Panel _A_ 是同一 FIGURE 3 中的独立 KM 子图;人群、终点或分析条件以本 Panel 图注语义为准。
FIGURE 3 · Panel _B_
Panel _B_ 是同一 FIGURE 3 中的独立 KM 子图;人群、终点或分析条件以本 Panel 图注语义为准。
FIGURE 3 · Panel _C_
Panel _C_ 是同一 FIGURE 3 中的独立 KM 子图;人群、终点或分析条件以本 Panel 图注语义为准。
FIGURE 3 · Panel _D_
Panel _D_ 是同一 FIGURE 3 中的独立 KM 子图;人群、终点或分析条件以本 Panel 图注语义为准。
这些图片未产生 KM 曲线结果,不在主页面重复展示。